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Abstract
Background: Across Western Europe, procedures and formalised criteria for taking decisions on the coverage (inclusion 
in the benefits basket or equivalent) of healthcare technologies vary substantially. In the decision documents, which 
display the justification of, the rationale for, these decisions, national healthcare institutes may employ ‘contextual 
factors,’ defined here as situation-specific considerations. Little is known about how the use of such contextual factors 
compares across countries. We describe and compare contextual factors as used in coverage decisions generally and 4 
decision documents specifically in Belgium, England, Germany, and the Netherlands. 
Methods: Four group interviews with 3 experts from the national healthcare institute of each country, document and 
web site analysis, and a workshop with 1 to 2 of these experts per country were followed by the examination of the 
documents of 4 specific decisions taken in each of the 4 countries, sampled to vary widely in type of technology and 
decision outcome.
Results: From the available decision documents, we conclude that in every country studied, contextual factors are 
established ‘around the table,’ ie, in deliberation. All documents examined feature contextual factors, with similar 
contextual factor patterns leading to similar decisions in different countries. The Dutch decisions employ the widest 
variety of factors, with the exception of the societal functioning of the patient, which is relatively common in Belgium, 
England, and Germany. Half of the final decisions were taken in another setting, with the consequence that no 
documentation was retrievable for 2 decisions.
Conclusion: First, we conclude that in these countries, contextual factors are actively integrated in the decision 
document, and that this is achieved in deliberation. Conceptualising contextual factors as both situation-specific and 
actively-integrated affords insight into practices of contextualisation and provides an encouragement for exchange 
between decision-makers on more qualitative aspects of decisions. Second, the decisions that lacked a publicly accessible 
justification of the final decision document raised questions on the decisions’ legitimacy. Further research could address 
patterning of contextual factors, elucidate why some factors may remain implicit, and how decisions without a publicly 
available decision document may enable or restrain decision-making practice.
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Implications for policy makers
• Situation-specific contextual factors feature in many healthcare coverage decisions; these decisions are not made based on criteria alone.
• Making healthcare coverage decisions requires expertise both in terms of contributing such contextual factors and making them part of the 
decision. 
• Despite apparent differences in level of formalisation of these contextual factors, countries in Western Europe appear to use similar contextual 
factor patterns. This may provide reasons for collaboration or exchange on more qualitative aspects of decision-making. 
Implications for the public
Those who make decisions on what should, and what should not, be provided in terms of healthcare (through a basic benefits package or national 
formulary) use considerations that vary per decision in doing so. These considerations make decisions more sensitive to the specifics of the type 
of healthcare they are deciding on and to the patients that hope to be helped by this technology. These considerations thus make the decision and 
its justification, or rationale, stronger. This research shows that there are similarities between decisions made in Belgium, England, Germany, and 
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Background
Challenging coverage decision dossiers on a specific 
healthcare technology may show up on desks placed in 
different countries around the same time.1 Within their 
varying healthcare systems, decision-makers are struggling 
with the exact same question: should our society pay for this?2 
The processes to arrive at an answer to this question have not 
been aligned across Western Europe, though there are strong 
similarities. Western European systems generally utilise 
some form of health technology assessment for healthcare 
technologies,3-6 which include technologies as wide-ranging 
as (orphan) drugs and medical devices, and “have clear 
objectives reflected in reimbursement criteria.”5 A formalised 
set of reimbursement criteria may, however, not necessarily 
wholly capture all reasons for or against coverage provided 
in a (publicly available) coverage decision document,7 which 
may result in differences between countries that might not 
be expected based on their respective formalised criteria 
sets.8-10 When surveyed, decision-makers indeed frequently 
acknowledge the presence of additional elements that impact 
coverage decisions. Scholars group such additional elements 
under umbrellas like ‘contextual factors.’3,10-16
What this umbrella of contextual factors holds exactly has 
recently attracted scholarly interest for ‘decisions of value’ in 
the healthcare field.17-20 Williams et al initiated the discussion 
with a literature review focused on meso-level decision-
making, exploring both ‘inner’ and ‘outer’ contexts and 
how these may affect such decisions of value.14 Many of the 
papers reviewed by Williams et al give ‘context’ as a relatively 
abstract explanation, and as something that is not necessarily 
visible in the final decision document. Examples from this 
review include organisational/institutional forces,21,22 political 
constraints,23 and economic climate or market forces.24,25 The 
field of Science and Technology Studies (STS), and Asdal 
specifically, challenges us to not use contexts as what she terms 
non-specific ‘explanatory resources.’26,27 Not content with 
doing away with context altogether either, Asdal encourages 
us to:
“[Grasp] the events of your study as, literally, unique 
events. (…) [Consequently,] the situation as the context that 
needs to be ‘recovered’ is that which conditions or enables a 
specific utterance to happen.”27
In essence, she sees context as present in a specific decision 
situation, traceable to a specific moment in time: as situation-
specific. This characteristic of situation-specificity, we argue, 
gives a handle on the contents of what Williams et al term 
“greater levels of judgement and intuitions” on the part of 
decision-makers.14 This paper follows suit in conceptualising 
contexts expressly not as external explanations for a situation 
and not as enduring backdrops of whatever kind, but rather 
as situation-specific entities that may be actively brought in 
by decision-makers. Moreover, we will term contexts that are 
present in the final decision documentation, which provides a 
justification, or rationale, for the decision, ‘contextual factors.’ 
In this, we narrow down and specify Williams et al’s original 
description of contextual factors.17 Of the contexts retrieved 
from literature by Williams et al, only 2 may be considered 
situation-specific, namely first, the information accessed by 
the decision-makers, or its absence, and especially high levels 
of uncertainty regarding this information; and second, the 
presence of specific interests impacting the decision. That 
the technology and its information would vary per decision 
may be considered logical; the latter finding resonates with 
situation-specific contexts identified elsewhere for macro-
level coverage decisions.13,28-31 
Although some of the papers reviewed by Williams et 
al describe minutely how the decision process unfolded, 
especially those included in the review by Vuorenkoski et al,10 
little is known about how these contexts are integrated in the 
justification of, the rationale for, the decision specifically, as 
this often remains implicit in line with the surveys of policy-
makers described above. To be precise, no studies have, to our 
knowledge, compared such use of contextual factors across 
countries (comparative papers primarily focus on the use of 
health technology assessment or related criteria such as cost-
effectiveness and conclude that if decisions “vary,” they do so 
due to “additional factors”8,32,33). This paper compares how 
situation-specific contextual factors are integrated in coverage 
decision documents in 4 Western European countries. 
Contextual factors will be operationalised here by means 
of a list of previously-described necessity argumentations.7 
Necessity argumentations have been shown to be used in 
coverage decisions around the world, but are not considered 
valid for every healthcare technology by everyone: their 
perceived validity varies per situation. These argumentations 
comprise a varied list, and include eg, the presence or absence 
of alternative treatments, the Rule of Rescue, the societal 
impact of (lack of) coverage, whether similar treatments are 
covered, medical necessity, and moral hazard considerations. 
Specifically, this research adds to existing literature by 
comparison of such contextual factor use in 4 widely varying 
healthcare technologies across 4 relatively similar countries 
in Western Europe, namely Belgium, England, Germany, and 
the Netherlands. 
Research Aim
This paper will explore situation-specific contextual factors in 
healthcare coverage decisions. We will answer the following 
main research question: how do Belgium, England, Germany, 
and the Netherlands use contextual factors in healthcare 
coverage decisions generally, and how does contextual factors 
use compare across 4 specific decisions? This study is divided 
into 2 parts. Part 1 examines how contextual factors are used 
in decision documentations generally through interviews and 
a workshop, enriched by document and web site analysis. 
Part 2 compares the contextual factors present in 4 specific 
decisions: nivolumab (Opdivo®), benzodiazepines, smoking 
cessation therapy, and walking aids with wheels, taken in 




This study describes the outcomes of an international research 
collaboration of decision-makers or policy advisors employed 
at 4 national healthcare institutes: National Institute for Health 
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and Care Excellence (NICE) in England; the German Federal 
Joint Committee (Gemeinsamer Bundesausschuss, G-BA); the 
Healthcare Knowledge Centre/National Institute for Health 
and Disability Insurance (HCKC/NIHDI) in Belgium; and 
the Dutch National Health Care Institute (Zorginstituut 
Nederland, ZIN) in the Netherlands with researchers from 
the Erasmus School of Health Policy & Management and 
the Erasmus School of Social and Behavioural Science, 
Rotterdam, the Netherlands on healthcare coverage decisions. 
For further information on the national healthcare institutes, 
please see section ‘working procedures’ in Supplementary file 
1. We provide an analysis of contextual factors in coverage 
decision documents generally (part 1 of the study) and in 4 
specific cases (part 2) in these 4 countries. 
We have chosen to compare countries in the understanding 
that comparative research need not be a linear-causal exercise, 
meaning here that a specific attribute of the country need not 
be offered as the explanation for an observed phenomenon.34,35 
Rather, this method was chosen because careful comparison 
of arguments and statements is thought to result in clearer 
definitions of these and more succinct questions for future 
research to address.35 Specifically, we started with semi-
structured, active interviews36 in groups. We enriched the 
interview data by document and web site analysis as well as an 
extensive member check (during the workshop, see below). 
We have opted to further extend the data gathered in part 
1 with case studies from the 4 countries.37,38 The reason for 
doing so is that comparison between cases that are similar 
(decisions on the same healthcare technology) taken in 
varying situations (the different countries) aids generating 
insight especially where valuation processes (cf. decisions 
of value14) are concerned.39 In addition, the cases represent 
maximum variability.40 In this way, by comparing the 
countries’ general decision-making processes with 4 decisions 
specifically, we have chosen a small ‘string of comparisons,’ 
which has the potential to bring stronger clarification.34 
To operationalise these contextual factors, we will employ 
necessity argumentations as our sensitising concepts.41 
Necessity is an umbrella term that encapsulates disease severity 
and need-related argumentations, which are situation-specific 
because they vary strongly per technology examined, and 
explicated and integrated by virtue of being used in decision 
outcomes. Necessity argumentations comprise patient-
specific considerations, such as above-mentioned disease 
severity, medical necessity and need, but also dignity, human 
rights and impact on societal functioning, and whether 
the condition the patient suffers from may be construed as 
‘normal experience.’ Related are the argumentations related to 
the patient population, such as whether the technology will be 
relevant for a small number of patients. Other considerations 
have to do with the technology and its availability, such 
as the presence or absence of alternative treatment and 
coverage of similar treatments, but also moral hazard (over-
usage) considerations. Another type of argumentation is 
society-related and concerns argumentations like societal (or 
individual) responsibility and impact of (lack of) coverage on 
wider society.
Necessity argumentations are used to provide a justification 
of, a rationale for, coverage decisions in several European 
countries, including France, Germany, Sweden, the United 
Kingdom, and the Netherlands.7 These argumentations are 
largely considered valid not only by decision-makers, but 
also by the public. In the overall study, the Netherlands was 
taken as the entry point in terms of country selection and 
overall study focus, because necessity has been described 
and used as a criterion for Dutch coverage decisions.42,43 
England, Germany and Belgium were selected as comparator 
countries because of their similarities in terms of ‘healthcare 
system objectives’ such as equity and affordability, but also 
transparency in decision-making.5 This was expected to result 
in a publicly available decision, enabling our data analysis.34 
The countries’ specific working procedures for decision-
making may be found in Supplementary file 1. 
Data Collection
The data collection consisted of 2 parts corresponding to the 
2 parts of the study: first, a round of semi-structured group 
interviews with experts, general policy document and web site 
analysis and a workshop with all the authors (for an overview, 
see Table 1); and second, document analysis of the 4 decisions 
taken across the 4 countries (for an overview, see Table 2). 
Part 1 of the data collection aimed to answer the first 
research question, was designed by authors AdB, BB, and 
TKV, and consisted of 4 semi-structured interviews, which 
were conducted in 2.5-3 hour conversations at each of the 4 
healthcare institutes. These semi-structured interviews were 
conducted by BB, JZ, and TKV and held with 1 national 
expert, who acted as the primary point of contact per institute 
and subsequently agreed to co-author this paper (MB, MP, 
and RvdV/JZ) and 2 colleagues, ie, 3 interviewees per country, 
with the exception of Belgium, who opted out of authorship. 
These national experts hold the following roles: former Head 
of HCKC, Director of the Centre for Health Technology 
Evaluation at NICE, Head of the Department of Medical 
Advice at G-BA, and the Chair and Secretary of the Appraisal 
Committee at ZIN.
An exception was the Dutch group interview, where 2 experts 
agreed to co-author this paper and only 1 additional colleague 
was present, and RvdV was interviewed 1 additional time by 
Table 1. Overview of Interviews and Workshops Comprising Part 1 of the Study
Interview Date Description
February 24, 2017
Appraisal committee ZIN group interview (RvdV, JZ, 
and a colleague)
March 17, 2017 HCKC/NIHDI group interview (RM and 2 colleagues)
April 6, 2017 G-BA group interview (MP and 2 colleagues)
June 23, 2017
NICE/NHS-England group interview (MB and 2 
colleagues)
October 18, 2017 Additional interview (RvdV)
December 13, 2017 Workshop at ZIN
Abbreviations: ZIN, Zorginstituut Nederland; HCKC/NIHDI, Healthcare 
Knowledge Centre/National Institute for Health and Disability Insurance; 
G-BA, Gemeinsamer Bundesausschuss; NICE, National Institute for Health 
and Care Excellence; NHS, National Health Service. 
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TKV (see Table 3). During the interviews, the interviewees 
all offered a deep understanding of their country’s healthcare 
decision processes and the use of contextual factors therein 
through giving a presentation on their decision-making 
procedure. This presentation was prepared beforehand, the 
interviewee giving the presentation was asked to provide 
information on the general coverage decision-making process 
in their country and its institutional bedding. They were 
also aware that the interviewers were interested in necessity 
argumentations in particular, and thus provided information 
on these types of considerations as well. This was followed by a 
presentation by TKV on what the interviewers understood as 
contextual factors (that is, necessity argumentations) and an 
extended group interview on the role of these types of factors 
on the decision-making process generally. The questions used 
to guide these interviews may be found in Supplementary 
file 2. The 4 semi-structured group interviews were audio-
recorded, transcribed, and coded for necessity argumentation 
use. These analyses were enriched by analysis of relevant 
policy documents and websites as offered by the interviewees. 
This was generally achieved by perusing the general websites 
of the respective institutes and documents pertaining to their 
working procedures in case of lack of clarity.
The findings gathered during the group interviews 
(supplemented by the information from the web site and 
document analysis) were presented by TKV at a one-day 
workshop, held in the Netherlands, attended by all authors 
(December 13, 2017). The explicit goal of this workshop was 
to gain deeper insight into the use of contextual factors in 
the different countries including similarities and differences 
as well as to provide a member check on the collected data. 
In addition, several analytical angles were discussed, and 
the decision to add part 2 of the research was made. Part 
2’s aim was to examine the final documentation pertaining 
to 4 decisions taken across the 4 countries of interest. Three 
inclusion criteria for the case studies were formulated:
1.	 Necessity argumentations feature prominently in the 
final documentation of the coverage decision in the 
Netherlands;
2.	 The coverage decision outcome varies in the 4 countries, 
with at least 1 outcome deviating from the rest;
3.	 The cases together represent maximum variation in the 
patterns of use of the argumentation types.7
For part 2, then, policy-makers employed at ZIN (JZ and 
a colleague) aided with choosing 8 cases that fulfilled the 
first criterion and that were sufficiently different in type of 
technology. Inclusion criteria numbers 2 and 3 narrowed the 
list down to 4 cases: nivolumab (Opdivo®), benzodiazepines, 
smoking cessation therapy, and walking aids with wheels. Of 
the 16 decisions (4 countries times 4 health technologies), only 




Package advice nivolumab (Opdivo®) including letter to the Minister of Health, Welfare, and Sports, dated 
December 8, 201544
Belgium Evaluation report day 90, Dossier 736 and 737, Second request report, dated July 6, 201645
England
NICE Technology appraisal guidance: Nivolumab for previously treated squamous non-small-cell lung cancer 
(TA483), dated November 1, 201746
Germany File for Benefit Assessment in accordance with section 35a of SGB-V, nivolumab (Opdivo®), dated April 28, 201647
Benzodiazepines
The Netherlands
Package advice 2009, Publication number 274, dated April 3, 200948
Letter to the Minister of Health, Welfare, and Sports, Reimbursement benzodiazepines, dated April 21, 200849
Belgium -
England
Generalised anxiety disorder in adults, the NICE guideline on management in primary, secondary and community 
care50






Help with smoking cessation: insured care?, dated June 30, 200852
Smoking cessation programme: insured care! Publication number 276, dated April 21, 200953
Belgium Effectiveness and cost-effectiveness of treatment for smoking cessation, HCKC, dated 200454
England Stop smoking interventions and services, NICE guideline (NG92), dated March 28, 201855
Germany
Regulation exclusion of medicines for heightening quality of life in accordance with Section 34 (1) Sentence 7 
SGB V (Lifestyle Drugs), Annex II to Section F of the Medicine-Directive, dated January 28, 201756
Walking aid with 
wheels
The Netherlands Report Medical aids 2010, Publication number 286, dated April 2, 201057
Belgium Memorandum main working group number 2003/6.4, Main group 1.4, Walking Aids Adults, dated July 14, 200358
England
https://www.nhs.uk/conditions/social-care-and-support-guide/care-services-equipment-and-care-homes/
walking-aids-wheelchairs-and-mobility-scooters/, dated August 8, 2018
Germany
GKV-Spitzenverband Update of the product group 10 "Walking aids" of the aid directory according to Section 139 
SGB- VvomAf, dated August 27, 201859
Abbreviations: HCKC, Healthcare Knowledge Centre;  NICE, National Institute for Health and Care Excellence; SGB-V, German Social Code, Book 5; GKV, National 
Association of Statutory Health Insurance Funds.
Note: For the English Benzodiazepines decision, please note that the second document analysed (Clinical guideline 113) is based on the former document.
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14 yielded a document to analyse, and 3 decisions yielded 2 
documents, to a total of 17 documents. Approximately half were 
obtained through website searches of the relevant institutes, 
with the other half contributed by experts or colleagues 
working at that country’s healthcare institute (for an overview 
of the documents analysed, see Table 2). TKV was aided by a 
student in analysing all coverage decision documents for the 
primary arguments separately, again using the list of necessity 
argumentations (Table 3) as codes, using good language 
skills in Dutch (for the Dutch and Belgian documents) and 
English and sufficient aptitude in reading German, aided by 
online translation and where needed by professionals who 
were directly involved in the coverage decision processes. The 
coding was done by TKV by specifically searching for forms 
of these 20 necessity argumentations. The outcomes were 
discussed by AdB, BB, and TKV in several iterative meetings, 
and all other collaborators commented on the resulting 
analysis and agreed upon the final text.
Results
This section provides an overview of how contextual factors, 
operationalised as necessity argumentations, generally play 
a role in each country, followed by a section on the use of 
contextual factors in the 4 case studies. A short introduction 
to the decision process in the different countries (derived 
from the website and policy document analysis and the 
presentation given by the interviewees during the semi-
structured interviews) may be found in Supplementary file 1.
Part 1: Use of Contextual Factors in General
From the presentations during the semi-structured group 
interviews in each of the 4 countries, as well as from the policy 
document and web site analysis, we conclude the following 
after introducing the interviewees to the list of necessity 
argumentations, sensitising them to the topics. 
According to the interviewees, their respective national 
healthcare institutes all use necessity argumentations as 
contextual factors in their decisions in addition to the 
formalised criteria (outlined below). Members of the research 
team easily provided examples where, in their eyes, a wide 
variety of these non-formalised, situation-specific contextual 
factors were employed. These examples included, but were 
not limited to: inclusion of smoking cessation (Belgium, 
see case study below); exclusion of homeopathy (England, 
decided by the National Health Service [NHS], perceived by 
interviewee as a necessity argumentation); exclusion of over-
the-counter medicines (England, due to low cost per patient); 
positive “Nikolaus decision” (Germany, due to a small number 
of patients); exclusion of immunisation for travel in free 
time (Germany, this falling under personal responsibility). 
Notably, the workshop attendees underlined that not all these 
argumentations might be identifiable in the final decision: 
sometimes these decisions were, apparently, ‘gut decisions,’ 
with reasons remaining implicit.
More generally, reflecting on the list of contextual factors, 
the Belgian interviewee stated: 
“[Contextualisation] will remain discursive all the time” 
(workshop, 13.12.2017).
This observation highlighted that contextualisation is left 
open to be established in argumentations in a deliberative 
setting: ‘around the table.’ It also accentuated the difference 
between contextual factors, which are situation-specific, and 
formalised criteria, which are not. This does not mean that of 
all the necessity argumentations, none have been formalised 
into criteria. In fact, the national healthcare institutes have all 
formalised the use of these contextual factors, but to different 
extents. 
Least formalised is Belgium, where no list of stringent 
criteria exists: rather, decisions are made, and contextual 
factors formulated, by different working groups. Some 
necessity argumentations are explicitly reflected in the 
criteria used in the Unmet Needs Programme, which features 
therapeutic need (discomfort, life expectancy, quality of life) 
and societal need (budget impact, incidence/prevalence), but 
this list is not widely used for decision-making.60
In England, the situation could be called most intricate. 
NICE general procedure turns on clinical and cost-
effectiveness, with thresholds for opportunity costs. Disease 
severity is formally included in the application of the ‘end-
of-life’ criteria, which allows additional flexibility only 
where a patient’s life expectancy is less than 2 years. It is also 
used in the deliberative decision-making process where the 
independent committee has the flexibility to accept cost-
effectiveness estimates that are higher than what would 
otherwise be considered value for money. Moreover, the NICE 
pre-selection procedure for highly specialised technologies 
employs elements like chronicity and acute death as criteria. 
For Germany, ‘necessity’ is 1 of 3 formalised criteria 
described in the German Social Code, Book 5 (SGB-V). 
However, it has not been specified to a great extent; the 
criteria in Germany are considered “generally formulated.”61 
Disease severity does influence the level of evidence required 
in G-BA’s decisions (varying from anecdotal evidence to 
randomised controlled trials).
The country with the highest formalisation is the 
Netherlands; ZIN operationalises necessity as 1 of 4 formal 
package criteria (next to effectiveness, cost-effectiveness, and 
feasibility). This is explicated in their formal documentations 
as disease severity, or individual burden of disease, and 
individual cost considerations.62,63
Part 2: Use of Contextual Factors in 4 Case Studies
The 4 decisions to be examined across the 4 countries, namely 
nivolumab, benzodiazepines, smoking cessation therapies, 
and walking aids with wheels, were selected per the criteria 
mentioned above, the documents analysed per decision are 
available in Table 2. Table 3 gives an overview of the used 
contextual factors per decision document per country.
Case Study 1: Nivolumab
All 4 countries decided on reimbursement of nivolumab for 
treatment of previously-treated squamous non-small-cell 
lung cancer. 
The expectation of a large budget impact necessitated 
placing nivolumab in the Dutch package lock, awaiting an 
advised decision by ZIN and, potentially, subsequent price 
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negotiations with the manufacturer.64 The Institute did indeed 
advise the Minister of Health against including nivolumab 
in the basic benefits package unless a price reduction of at 
least 40% could be achieved: the treatment was considered 
effective, but not cost-effective enough. In their decision 
documentation, the Institute argued that: “the burden of 
disease is high” as it is considered “a non-curative disease” 
with “limited life expectancy.” Interestingly, an alternative 
treatment (docetaxel) is mentioned in the pharmaco-
economic report. Moreover, “the costs for the treatment is 
so high patients cannot be expected to pay.”44 The Minister 
did negotiate, and although the final price has not been made 
public, nivolumab is now available on the Dutch benefits 
package. 
For Belgium, the official documentation retrieved 
is the ‘day 90’ report from the Committee for ‘advance 
compensation’ for Pharmaceuticals, and specifically the 
‘second request’ document, which gives the latest insight into 
motivation concerning reimbursement and the details of the 
final coverage arrangement for nivolumab. The necessity 
argumentations visible are “weakness and fatigue, coughing, 
shortness of breath, pain” and a median survival number. 
Moreover, considerations around the quality of life feature in 
the comparison with doxacetel.45 This resulted in a positive 
decision.
As for ZIN, NICE’s Technology Appraisal Committee 
considered nivolumab effective but not cost-effective enough. 
Moreover, the uncertainty of the evidence was deemed too 
great. For these reasons, additional characteristics were 
considered: in the social value judgement several necessity 
argumentations were brought to the fore. The committee 
noted a high need due to lack of alternatives, with a high 
Table 3. Overview of Contextual Factors Operationalised as Necessity Argumentations and Their Respective Descriptions7 Combined With Information on Which 
Factor Was Used in Which Decision in Which Country






Whether the ailment is considered an illness for which 
treatment is necessary
NL NL, BE, EN, DE
Equity/Fairness/
Justice
Whether coverage would be necessary to counter injustice/
inequity/lack of fairness in (access to) treatment
NL, EN
Individual Cost
Whether lack of coverage would stop patients from buying 
necessary care themselves due to prohibitive cost
NL NL NL NL
Individual 
Responsibility




Whether or not a treatment is considered to be “medically 
necessary” or a “medical necessity”
NL
Morbidity/Severity
Whether the physical and/or psychosocial morbidity 
associated with a certain ailment constitutes such a need 
that coverage is considered necessary
NL, BE, EN, 
DE
NL, EN NL, BE, EN BE, EN, DE
Need
The extent to which the patient is considered to be in need 
for which treatment is necessary




Whether or not viable alternatives are considered to be 
present which would make coverage more or less necessary
NL, BE, EN NL, EN DE
Patient-Diagnosis




Whether the experience of the patient is considered normal 




Whether similar treatments are covered or not (meaning that 
this type of treatment is considered necessary) NL, DE
Societal Impact
Whether coverage is considered necessary to allay the 
impact this disease has on people beyond the patient
NL, BE
Societal Functioning
Whether coverage would aid a person’s necessary 
functioning in society
BE, EN EN NL, DE BE, EN, DE
Vulnerability/
Compassion
Whether a compassionate response to vulnerable groups, 




Whether other (eg, heavier dosage or more expensive than 
necessary) medicines or care would be consumed or used by 
patients as a result of a negative coverage decision 
NL
Under-consumption
Whether less medicines or treatments than necessary would 
be consumed or used by patients as a result of a negative 
coverage decision (the direct opposite of ‘Moral Hazard’)
NL
Abbreviations: NL, the Netherlands; BE, Belgium; EN, England; DE, Germany.
Note: The argumentation types that were not present in this data set (namely, Dignity, Human Right, Moral Hazard, Rule of Rescue, Small Number of Patients, 
and Societal Responsibility) were omitted from this table.
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morbidity, a low life expectancy, and “symptoms which are 
difficult to manage.”46 This resulted in a recommendation 
of funding, but only through the Cancer Drugs Fund, which 
happened after a renegotiation on the price of nivolumab with 
manufacturer Bristol-Myers Squibb.65
In Germany, drugs are covered with market entry, followed 
by a decision on additional benefit by G-BA, which may be 
used in turn for price negotiations. In the case of nivolumab, 
the Institute for Quality and Efficiency in Health Care (Institut 
für Qualität und Wirtschaftlichkeit im Gesundheidswesen) 
provided evidence concerning mortality, morbidity, quality of 
life, and several adverse event categories, noting considerable 
added benefit on all counts for non-small-cell lung cancer 
patients on nivolumab to benefit the decision made by G-BA. 
In terms of necessity argumentations, the report mentions the 
severity of the disease, the low absolute 10-year survival rate 
and the “need for drugs.” The Individual Cost is mentioned 
but not clearly as an argumentation.47 This was sufficient 
grounds not to exclude nivolumab from coverage.
Case Study 2: Benzodiazepines
In the Netherlands, ZIN advised the Minister of Health 
against continued coverage of benzodiazepines.48,49 The 
primary reasoning was that although the indication was 
for short-term use, prescriptions for benzodiazepines often 
ended up to be for chronic use. The Institute recommended 
improving the guidelines, but consultation with field parties 
revealed difficulties in defining eligibility criteria. Therefore, 
even despite the disease severity mentioned and the fact 
that short use of benzodiazepines following the applicable 
guidelines may be medically necessary (but chronic use 
not), the large amount of chronic users, the possibility that 
denying coverage would lead to patients choosing another, 
covered, medicine and the fact that the cost for 1 episode of 
benzodiazepines is approximately €12-16 were decisive in 
the negative coverage decision. The exception was made for 
3 clearly defined indications: epilepsy, anxiety disorders, and 
multiple psychiatric disorders. 
For the Belgian case, treatment of benzodiazepines is not 
covered by the health insurance. NIHDI has never appraised 
benzodiazepines as they have never received a request to do 
so. 
In England, NICE guidelines recommend short-term use 
of benzodiazepines for several medical indications, which 
have separate appraisal documents. We analysed the case of 
adult generalised anxiety disorders which highlights several 
risks for general practitioners prescribing benzodiazepines, 
which fall under necessity argumentations. First, emphasis 
is laid on the high frequency of over-use due to tolerance 
and dependence. The documentation does highlight that 
use is only recommended in case of non-response to other 
medicines, which can be classed as an argumentation in 
favour of coverage. People with generalised anxiety disorder 
are described to have “long-standing and often uncontrollable 
worries and negative thoughts” which affect their “many areas 
of their lives, particularly relationships, self-esteem, daily 
activities, employment, work life and education.”50,51
G-BA has, like NIHDI, never received an appraisal 
request for benzodiazepines, but in contrast to Belgium, 
benzodiazepines are covered by the German sickness funds. 
The reason is that in Germany all drugs are covered after 
market entry except when they are specifically excluded either 
by law in the SGB-V or by G-BA. A systematic assessment of 
additional benefit (for the sake of price negotiations) was only 
established in 2011 by the Act on the Reform of the Market for 
Medicinal Products. Benzodiazepines were on the German 
market in 2010 already and are thus part of a “historical 
benefit package.”
Case Study 3: Smoking Cessation Therapies
This analysis is of decisions for both psychotherapeutic and 
pharmaceutical smoking cessation therapies.
In the Netherlands, ZIN dealt with several iterations of the 
coverage decision for smoking cessation therapies: they were 
covered, then no longer covered, and then covered again. 
One reason is that it became a political issue with changes 
in government affecting the reimbursement status. The 
final advice to the Minister has been to cover stop advice, 
intensive forms of interventions for behavioural change, 
and nortriptyline, but not several other interventions. The 
final decision hinged, at least partially, on the effectiveness: 
in essence, the health gain even a few extra successful stop 
attempts would yield, also visible in the argumentation that 
“a smoking cessation programme can reduce the damage 
caused by smoking to others.” In this extensive decision-
making process, several necessity argumentations played a 
role.53,54 First, the individual is personally responsible for his 
health, and the costs for the individual were low, reducing the 
perceived necessity of coverage. Even so, there were indications 
that more people would attempt to quit smoking if it was 
covered, and especially those with a lower socio-economic 
status. Moreover, smoking was defined as an addiction and 
bad for health, leading to quality of life loss, causing damage 
to others, including unborn children and infants, treatment 
for which is usually covered by the basic benefits package. 
Smoking cessation therapies have never formally been 
discussed by the committee for Reimbursement of Medicines 
at Belgian NIHDI. Not the mutualities, but the Belgian 
National Cancer Initiative covers €20 of the first 8 sessions 
of smoking cessation therapies66 and from January 1, 2017, 
smoking cessation aid by a tobaccologist is reimbursed in 
Flanders.67 As in the Netherlands though, these therapies 
have not always been covered for everyone. The compulsory 
health insurance covered smoking cessation therapies for 
all pregnant women, revealing a potential Societal Impact 
argumentation, though this was rarely used. In 2004, HCKC 
published a report that all smoking cessation therapies are 
cost-effective that informed what is now a primary part of 
the National Cancer Initiative. This report was not a coverage 
decision, but analysis yielded that smoking was defined as a 
habit, strong descriptions of the morbidity caused by smoking, 
including the increased risk of having a baby with low birth 
weight.54
In England, smoking cessation therapies are available to all 
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citizens over 12 years of age, for which NICE most recently 
published guidelines in 2018. These highlighted that “smoking 
is the main cause of preventable illness and premature death” 
and showed that all smoking cessation therapies were cost-
effective enough to stay below the QALY threshold. The 
guidelines underscore that there are social inequalities in 
terms of tobacco use, which “make a significant contribution 
to inequalities in health.”55
Germany is the only of the 4 countries analysed in this 
project that does not cover smoking cessation therapies, as 
they are excluded from the benefits package by law (SGB-V 
§34). The title of the analysed documentation reveals they are 
considered “lifestyle medicines” aimed at improving quality 
of life, but no additional contextual factors are visible in the 
documentation. 
Case Study 4: Walking Aids With Wheels (Rollators)
We analyse walking aids with 2, 3 or 4 wheels, also called 
rollators, for adults. 
In the Netherlands, the Minister of Health was advised by 
ZIN to no longer include mobility aids in the basic benefits 
package, and 2 necessity argumentations were given for this. 
First, the cost for walking aids with wheels, crutches and many 
more walking aids was considered too low and secondly, “a 
walker with wheels is for common use,” meaning that it was, 
in Dutch society, considered normal to need one at a certain 
age.57 
The Belgian NIHDI has published prescription guidelines 
which cover walking aids with wheels for those unable to 
stand up independently or safely.58
In England, this intervention has not been considered 
by NICE, but the NHS loans walking aids with wheels for 
free, after assessment by a physician. No specific appraisal 
documents were available for walkers with wheels, as they are 
only discussed in guidelines for specific conditions, which 
only specify that “you or someone you know” needs to have 
“difficulty walking or getting around (mobility).”68
Despite the fact that G-BA has not appraised walking aids 
with wheels specifically, they are available to all German 
citizens from their insurers upon indication: anyone 
experiencing reduced physical mobility or loss of balance is 
considered eligible, as long as other mobility aids have proved 
insufficient. This list is managed by the National Association 
of Statutory Health Insurance Funds (GKV-Spitzenverband).59 
 
Comparison of Contextual Factor Use in the 4 Cases
To start, across these cases, similar patterns in contextual 
factor use lead to similar decision outcomes. This is visible 
in 5 instances. First, there are strong similarities between the 
decisions for nivolumab in Belgium and Germany, which 
both strongly rely on the severity of the disease and patients’ 
quality of life and need, as well as the low survival rate. The 
other 2 decisions for nivolumab are highly reminiscent 
of these argumentations, but the Dutch and English both 
used them as input for price negotiations (which means the 
initial decision was negative). England and the Netherlands 
also strongly overlapped in their argumentation pattern for 
benzodiazepines, invoking the large amount of chronic users or 
over-usage as a reason to limit coverage, while acknowledging 
the difficulties experienced by the patient as well as the lack of 
alternatives. Fourth, there are some similarities between the 
Dutch and English decision for smoking cessation therapies, 
too, though the Dutch decision-making process featured a 
far greater number of contextual factors. Finally, the Belgian, 
English, and German decisions for walking aids with wheels 
also show strong overlap: if you are unable to stand up safely 
in these countries, a walking aid with wheels is provided for 
in some way. 
Moreover, it would seem that the number of contextual 
factor types considered valid in one or more of the cases 
varies between the countries: the Belgian decisions feature 7 
types, the English also 7 types, the German decisions 6 types, 
compared to 16 types of contextual factors present in the 
Netherlands. This shows that the Dutch decisions generally 
feature a high amount of contextual factors in this data set.
Finally, half the (final) decisions were not taken by the 
institutes analysed. This pertains to the Belgian and German 
benzodiazepines decisions, the Belgian and German smoking 
cessation therapies decisions, the English and German 
walking aids with wheels decisions and, to an extent, the 
Dutch nivolumab decision as it differed from the initial ZIN 
advice, and the English nivolumab decision as it was covered 
through the CDF rather than a positive decision by NICE. 
Many of these did, however, yield a document or web site 
to analyse (only 2 benzodiazepines decisions lacked such a 
decision document). 
Discussion
Contextualisation has recently been a raised as an important 
topic of interest for both policy practice and research regarding 
healthcare ‘decisions of value.’14 Our cross-country research 
team has defined contextual factors as situation-specific 
considerations, following Asdal.27 This enabled us to examine 
the coverage decision processes in 4 Western-European 
countries: Belgium, England, Germany, and the Netherlands, 
and specifically, to establish where contextual factors are 
used, both generally (part 1 of the study) and in 4 decisions 
taken across the 4 countries specifically (part 2). We have 
operationalised these situation-specific contextual factors 
using a list of previously-described necessity argumentations 
that are used across Europe and generally vary per decision.7
We draw the following conclusions. From part 1 of 
the study, we conclude that situation-specific contextual 
factors, operationalised as necessity argumentations, are 
present in decision-making processes at HCKC/NIHDI in 
Belgium; NICE in England; G-BA in Germany; and ZIN in 
the Netherlands. Some necessity argumentations have been 
formalised into criteria to be used for every decision in 
theory (individual burden of disease in England, Germany, 
and the Netherlands, and individual cost considerations in 
the Netherlands).62,69-71 This may raise the question whether 
these would fall outside the definition of contextual factors 
as situation-specific – however, our data show that not every 
decision analysed uses these formalised contextual factor(s) 
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in practice. Specifically, expert interviewees underline that 
contextual factors are determined in deliberation, ‘around 
the table’: a setting present in some form at every institute 
studied.61 They offered many examples of specific decisions in 
which such factors were considered, though underlining that 
not all of these factors had been explicated in their respective 
documentations.
From part 2, we conclude that similar patterns in contextual 
factor usage lead to similar decisions in the countries 
studied (Belgium and Germany for nivolumab; England 
and the Netherlands for nivolumab and benzodiazepines; 
and Belgium, England and Germany for walking aids with 
wheels). This is an important conclusion, which may serve 
to encourage exchange between decision-makers in different 
countries on more qualitative aspects of coverage decisions in 
addition to the current collaborations on the more quantitative 
aspects. However, the decisions are still sufficiently different 
(in fact, they were explicitly selected as having different 
outcomes across the 4 countries) to preclude much more 
than exchange. The use of contextual factors in decisions, we 
would argue, would need to remain at the discretion of local 
decision-makers. In this data set, Dutch decisions employ the 
widest variety of contextual factors, and most often employ an 
argumentation type no other country employs. This with the 
notable exception of the societal functioning of the patient, 
which is a common consideration in Belgium, England, and 
Germany. This shows that in a sense, the argumentations 
are not 100% situation-specific. Instead, they are part of 
typifications, and these types are identifiable across situations, 
but not consistently. It is thus the pattern of contextual factors 
that is truly situation-specific.29,72 Future research could 
further address this idea of patterning, and how it influences 
coverage decisions. Finally, for all 4 institutes some decisions 
in this data set are taken or retaken by another actor, which 
often sometimes means that the documentation for the final 
decision is not publicly available. 
Taking a step further in conceptualising contextual factors, 
we conclude that they are explicated around the table, in 
deliberation. This establishing around the table is the first 
element: we also conclude that contextual factors need to be 
actively integrated in the decision documentation, as not all 
factors established in deliberation seem to be present in the 
document.  Many scholars have in fact described, often based on 
interviews, that many such contextual factors remain implicit, 
either in both the deliberation and the documentation, or in 
the documentation only. This is perhaps to be expected, as 
localised processes of meaning-giving by the decision-makers 
themselves are described as implicit.73,74 We conclude, as 
Mann puts it, that contextualisation is an intervention,75 and 
as such, an active, situated process. As a consequence, this 
conceptualisation of contextual factors attunes us to effect 
that decision-makers have on how decisions are justified, 
and the expertise they bring to bear therein. The fact that 
these differences in explication of factors exist is of particular 
interest as it provides more insight into the how and why 
of evidence-informed deliberative processes.76,77 Further 
research should address why and how some factors remain 
implicit, whereas others are not only explicated but actively 
integrated in the final text.
Many of the documentations that should provide a 
justification/rationale for the final decision were, in fact, 
absent, and an alternative document was analysed if present. 
For some, we analysed the pre-final decision (nivolumab 
for England and the Netherlands, both negative decisions), 
in other cases, the decision was not taken by the national 
healthcare institute (walking aids with wheels for England 
and Germany), in others again, no decision was visible at all. 
This underscores that healthcare coverage decision-making is 
a process that involves many people in many places. It is a 
question of definition (‘does a decision on technology X fall 
under the remit of our national healthcare institute?’) but 
also a question of agenda setting (eg, NIHDI and G-BA had 
never received a request to appraise benzodiazepines). This 
backdrop to the decision is something that is not explicitly 
integrated into the documentation, but is definitely actively 
shaping the final decision.
This high prevalence of decisions for which the final 
documentation is not available is a particularly salient 
finding, as this highlights that the transparency of some 
decisions may be limited. Because these (final) decisions 
are made in another setting, the argumentations underlying 
the decision remain unknown. This is intriguing as many 
of the institutions studied are seeking to make processes 
more transparent in pursuit of increasing the legitimacy of 
their decisions.5 A more transparent decision is considered 
to heighten the legitimacy of this type of public decisions in 
general.78-85 Moreover, many authors hold that the coverage 
decision process should be based on consistently-applied, 
formalised criteria, visible in the documentation pertaining 
to the decision, and that having highly formalised criteria 
would potentially enable more rational, better-justifiable 
decisions.86-90 Yet, the Dutch nivolumab decision in particular 
demonstrates that having highly formalised criteria, as is the 
case in the Netherlands, does not preclude this particular type 
of decision-making. Further research may carefully consider 
the ways in which these ‘invisible’ decisions enable and 
restrain deliberative coverage decision-making practice, and 
how this relates to the legitimacy of these decisions.91
Strengths and Limitations
Our paper covers a vital topic as it successfully visualises the 
contextual factors employed in coverage decisions generally 
and 4 decisions specifically in 4 countries. This paper does 
so without resorting to using general healthcare system 
characteristics as an explanation but instead seeks to draw 
more specific conclusions. Another strength of the paper lies 
in the methodology, and especially the case study selection, 
which was both grounded empirically through expert 
interviews and enriched by theoretical interest through the 
formulated criteria. 
As the Netherlands was taken as the entry point for this 
study, both in terms of content as in terms of the place of work 
and residence of the majority of the authors, this will have had 
a significant impact. In particular, this is visible first, in terms 
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of the case selection (as Dutch interviewees were asked for 
the initial list of potential cases); second, in the level of detail 
acquired in the case descriptions, which is relatively high for 
the Dutch decisions. It is also likely that it may have affected 
the research question itself. Asking questions concerning 
formalisation, or operationalisation, of criteria may be 
considered a typically Dutch pursuit, as visualised by the fact 
that the Netherlands has a rich history in terms of seeking to 
explicate decision criteria in this context.42,69,71 
The use of necessity argumentations has narrowed the 
subject down content-wise to considerations that are likely 
to be present in decision documents. Future research could 
investigate how what remains implicit impacts decision-
making. It is also important to note that the decisions studied 
span the last fifteen years, and it is likely that considerations 
are weighed or valued differently across that time span. Future 
research could address how the use of contextual factors may 
change over time.
As Bærøe noted,17 there is a difference between approaches 
aiming to formulate a comprehensive list, and those that 
would hold that this is impossible. Although we have 
chosen a limited list as it facilitates this research, we do not 
necessarily believe that an exhaustive list would be possible. 
Normatively this may well prove problematic; for this study, 
we are concerned with describing what is rather than with 
what ought to. 
Conclusion
This study aims to be part of answering the recent call for 
research in aid of understanding practices of contextualisation. 
As healthcare coverage decisions are a particularly fruitful 
area to study these practices in, we have compared the use of 
contextual factors, defined as situation-specific considerations, 
in documentations that provide a justification, or rationale, of 
these decisions as offered by HCKC/NIHDI (Belgium), NICE 
(England), G-BA (Germany), and ZIN (the Netherlands). To 
study these, we employed group interviews with 3 national 
experts per institute, document and web site analysis, and 
a workshop with 1 to 2 experts per country (together part 
1), and the analysis of 4 different case studies across these 4 
countries, which varied greatly in terms of type of technology 
(part 2). From this data set, we conclude that these 4 national 
healthcare institutes all utilise situation-specific contextual 
factors in their decision documents. These contextual 
factors are employed ‘around the table,’ that is, established in 
deliberation. Though some may remain implicit, others are 
not only explicated, but actively integrated in the decision 
documentation, thus strengthening the decision by making it 
more sensitive to the case at hand. Moreover in this data set, 
there are strong similarities in terms of how these contextual 
factors are used: similar patterns of contextual factor use lead 
to similar decisions in different countries. These observations 
do not use context as non-specific explanatory resources, 
as critiqued by Asdal in particular,26,27 but instead focus on 
the people and their processes required to actively integrate 
these considerations. It also calls for future research on 
patterning of these contextual factors in deliberative settings. 
Not all decisions are taken ‘around the table,’ however. Half 
the decisions were taken or retaken in another setting, with 
the documentation to back up the final decision sometimes 
completely absent. We note this may impact the legitimacy of 
these decisions, and call for future research efforts on how this 
may affect the daily practice of coverage decision-making. 
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